**SUBJECT:** MRSA Nasal Screening Protocol for Antimicrobial Stewardship

**DATE ISSUED:** [Date policy created]

 [Hospital Logo]

**LAST REVIEWED:** [Date policy revised]

**PREVIOUS VERSIONS:** [Date previously reviewed or revised]

**APPROVED BY:** [Approving individual or committee]

**Background**

The absence of MRSA detection via nares swab can be used as an antimicrobial stewardship tool to de-escalate or avoid

empirical anti-MRSA agents for many different infection types and sites, including pneumonia, skin/soft tissue, diabetic foot, urine, blood, intra-abdominal, and orthopedic infections. However, the low positive predictive value makes a positive MRSA nares screening unsuitable for predicting subsequent MRSA in a clinical culture. Pharmacist-driven protocols for MRSA nares screening have been shown to reduce vancomycin utilization without compromising clinical outcomes.

**Purpose**

To allow pharmacists to order nasal MRSA PCR swabs per protocol to facilitate de-escalation of empiric antibiotic coverage of MRSA, if a nasal MRSA PCR swab has not already been ordered by the provider.

**Policy**

Nasal MRSA PCR screening will be utilized to guide de-escalation of empiric coverage of MRSA with the following exclusions:

* + Nasal MRSA PCR test performed within the last 7 days
	+ MRSA in any culture in the last 12 months
	+ De-colonized for nasal MRSA with mupirocin in the last 3 months
	+ Cystic fibrosis patients (due to lower respiratory MRSA colonization independent of nasal colonization status)

**Procedures**

1. Pharmacist responsibilities
	1. Enter order for nasal MRSA PCR screen for new empiric vancomycin, linezolid, or daptomycin orders in the electronic health record within 24 hours. See above for exclusions.
	2. Orders will be entered using the [“Per protocol, cosign required”] mode
	3. If negative, the pharmacist will contact the provider to discuss clinical appropriateness of de-escalation of anti-MRSA therapy
	4. If positive, refer to cultures to determine if MRSA remains a likely causative pathogen. Recommend de-escalation of anti-MRSA therapy based on cultures and patient’s clinical course.
2. Nursing responsibilities
	1. Once an order for an MRSA nasal screen is received, nursing will collect the swab via standard technique and send the specimen to lab for processing as soon as possible.
3. Provider responsibilities
	1. Follow up on nasal MRSA PCR and de-escalate MRSA antibiotic coverage if negative and clinically appropriate.
	2. If positive, refer to cultures to determine if MRSA remains a likely causative pathogen. Consider de-escalation of anti-MRSA therapy based on cultures and patient’s clinical course.
	3. Providers are also encouraged to order nasal MRSA PCR screen when initiating vancomycin, linezolid, or daptomycin orders. See above for exclusions.

**References**

1. Baby, Nidhu, et al. "Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in Patients with Suspected MRSA Pneumonia." Antimicrobial Agents and Chemotherapy 61.4 (2017): e02432-16.
2. Willis C, et al. "Impact of a pharmacist-driven methicillin-resistant Staphylococcus aureus surveillance protocol." American Journal of Health-System Pharmacy 74.21 (2017): 1765-73.
3. Smith EA., et al. "Nasal methicillin-resistant Staphylococcus aureus screening in patients with pneumonia: A powerful antimicrobial stewardship tool." American Journal of Infection Control (2017).
4. Dangerfield B, et al. "Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia." Antimicrobial Agents and Chemotherapy 58.2 (2014): 859-64.
5. Parente DM, et al. "The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications." Clinical Infectious Diseases 67.1 (2018): 1-7.
6. Mergenhagen KA, Starr KE, Wattengel BA, et al. "Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship." Clinical Infectious Diseases 71.5 (2020): 1142-1148.
7. Meng L, Pourali S, Hitchcock MM, et al. "Discontinuation Patterns and Cost Avoidance of a Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus Nasal Polymerase Chain Reaction Testing Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia." Open Forum Infectious Diseases 8.4 (2021): ofab099.
8. Metlay J, Waterer GW, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. ATS Journal. (2019).

Reviewed by: Jenna Preusker, PharmD, BCPS, BCIDP, Danny Schroeder, PharmD, BCPS and Juan Teran Plasencia, MD